Results 161 to 170 of about 38,676 (197)

Exceeding expectations: factors contributing to the potency of human papillomavirus vaccines. [PDF]

Lancet Microbe
Schiller JT, Kines RC, Day PM, Çuburu N, Kreimer AR, Lowy DR.   +5 more
europepmc   +1 more source

Informative High-Risk HPV Genotyping in Cervical Cancer Screening: Integrated Analysis of Cytology and p16/Ki67 Dual Staining. [PDF]

Cancers (Basel)
Trzeszcz M, Mazurec K, Mazurec M, Kobierzycki C, Halon A, Jach R.   +5 more
europepmc   +1 more source

Development of a 12-Valent HPV L1 Virus-like Particle Vaccine Using an Enhanced Baculovirus Expression System. [PDF]

Vaccines (Basel)
Kim JD, Kim EH, Lee JH, Kim SY, Oh JM, Cho Y, Kim H, Gwak W, Woo SD, Han BK, Choi JB.   +10 more
europepmc   +1 more source

HPV Exposure in the Gynecological Practice: Time to Call It an Occupational Disease? A Systematic Review of the Literature and ESGO Experts' Opinion. [PDF]

Vaccines (Basel)
Ege HV, Temiz BE, Grigore M, Burney Ellis L, Bowden SJ, Lopez-Cavanillas B, Preti M, Zapardiel I, Joura E, Gültekin M, Kyrgiou M.   +10 more
europepmc   +1 more source

Assessment of Mycobacterium tuberculosis dodecin scaffold as a multimerization platform on the immunogenicity of HPV L2 antigens. [PDF]

Sci Rep
Kaplan E, Mariz FC, Zhao X, Nessling M, Veitl L, Zhang Y, Weyd H, Müller M.   +7 more
europepmc   +1 more source

Preclinical Assessment of a New Virus-like Particle-Based Quadrivalent Human Papillomavirus Vaccine in Animal Models. [PDF]

Vaccines (Basel)
Mohammadi Barzelighi H, Naderi Saffar Z, Pakatchian E, Taqavian M, Javadimehr B, Safaeian M, Abbaszadeh P, Jalili H.   +7 more
europepmc   +1 more source

RNF112 mediates immunosuppression to inhibit the proliferation of cervical cancer by Foxm1. [PDF]

Transl Cancer Res
Pan H, Bao L, Shi W, Wan J.
europepmc   +1 more source

An mRNA-encoded scFv antibody targeting the helix-α3 of HPV18 E7 oncoprotein as a novel antiviral strategy. [PDF]

mBio
Han F, Guo X-y, Cui L-y, Zhang M-x, Zeng Y-r, Wang G-q, Li J-j, Chi X, Jiang M-x, Xiong Y-t, Zhou L-z, Zheng Q-b, Yu H, Zhang J, Li T-t, Gu Y, Xia N-s, Li S.   +17 more
europepmc   +1 more source

Immunogenicity of an <i>Escherichia coli</i>-Produced Recombinant 9-Valent Human Papillomavirus Vaccine in Mice and Rats. [PDF]

Vaccines (Basel)
Liu YY, Yin F, Li WJ, Chen D, Wu SM, Chen X, Wang Y, Yang ZM, Zhang HJ, Liu YJ.   +9 more
europepmc   +1 more source

Transient receptor potential canonical 3 is required for HPV-induced malignant transformation of cervical epithelial cells. [PDF]

Commun Biol
Tan Y, Huang Q, Zeng J, Wang Y, Yang S, Yu L, Wei J, Wei Y, Zhao J, Chen J.   +9 more
europepmc   +1 more source